Ming Sheng Yu

US Patent:

20110142815, Jun 16, 2011

Filed:

Jan 4, 2010

Appl. No.:

12/667687

Inventors:

Ming YU - Los Angeles CA, US

International Classification:

A61K 31/41
A61K 38/43
A61K 31/7052
C12N 5/09
A61P 35/00

US Classification:

424 941, 514381, 514 44 A, 435375

Abstract:

This invention describes methods and pharmaceutical compositions for combinational cancer treatments that are capable of inducing JNK phosphorylation and induce programmed cell death. It also identified genes as target for anti-cancer drug development and enhancement of the chemotherapeutic drug effect for the treatment of cancer. This invention points to a novel method and principle for a new avenue of developing more efficient and low or non cytotoxic cancer treatment.

US Patent:

20170081662, Mar 23, 2017

Filed:

Sep 26, 2016

Appl. No.:

15/275863

Inventors:

Ming Yu - Los Angeles CA, US

International Classification:

C12N 15/113

Abstract:

This invention points to biological molecules and/or sequences that can be used as target for designing drug for treating cancer. This invention also points to biological sequences that can be used to target those molecules as a mean to treat cancer.

US Patent:

20140163088, Jun 12, 2014

Filed:

Jan 9, 2014

Appl. No.:

14/151539

Inventors:

Ming YU - Los Angeles CA, US

International Classification:

A61K 31/713
A61K 45/06
A61K 31/47
C07D 257/04
A61K 31/41

US Classification:

514 44 A, 548252, 514381

Abstract:

This invention describes methods and pharmaceutical compositions for combinational cancer treatments that are capable of inducing JNK phosphorylation and induce programmed cell death. It also identified genes as target for anti-cancer drug development and enhancement of the chemotherapeutic drug effect for the treatment of cancer. This invention points to a novel method and principle for a new avenue of developing more efficient and low or non cytotoxic cancer treatment.